Nerviano Medical Sciences signs agreement with Genentech for antibody drug conjugates - MarketLine Financial Deals

Nerviano Medical Sciences signs agreement with Genentech for antibody drug conjugates

Nerviano Medical Sciences signs agreement with Genentech for antibody drug conjugates - MarketLine Financial Deals
Nerviano Medical Sciences signs agreement with Genentech for antibody drug conjugates
Published Oct 21, 2008
2 pages — Published Oct 21, 2008
Price US$ 45.00  |  Buy this Report Now

About This Report

  
Abstract:

Nerviano Medical Sciences (NMS), an Italy-based oncology-focused discovery and development company, has signed a multi-year research agreement with Genentech, Inc., a US-based biotechnology company, for the discovery of antibody drug conjugates for the development of potential anticancer agents. Under the agreement, Genentech would have the exclusive license to fully develop and commercialize licensed products that contain such antibody drug conjugates. During the research program, NMS would be primarily responsible for synthesizing and manufacturing drug reagents, while Genentech would generate antibody drug conjugates with such drug reagents and further evaluate their potential therapeutic utility.

  
Source:
Document ID
MA00292_081023
Country
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Nerviano Medical Sciences signs agreement with Genentech for antibody drug conjugates" Oct 21, 2008. Alacra Store. Dec 09, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Nerviano-Medical-Sciences-signs-agreement-with-Genentech-for-antibody-drug-conjugates-2052-232>
  
APA:
MarketLine Financial Deals. (2008). Nerviano Medical Sciences signs agreement with Genentech for antibody drug conjugates Oct 21, 2008. New York, NY: Alacra Store. Retrieved Dec 09, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Nerviano-Medical-Sciences-signs-agreement-with-Genentech-for-antibody-drug-conjugates-2052-232>
  
US$ 45.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.